LEADER 05200nam 2200613Ia 450 001 9910841167403321 005 20230721004735.0 010 $a1-282-68309-8 010 $a9786612683091 010 $a3-527-62273-X 010 $a3-527-62274-8 035 $a(CKB)1000000000707663 035 $a(EBL)482031 035 $a(OCoLC)352869288 035 $a(SSID)ssj0000112451 035 $a(PQKBManifestationID)11830358 035 $a(PQKBTitleCode)TC0000112451 035 $a(PQKBWorkID)10097324 035 $a(PQKB)10896151 035 $a(MiAaPQ)EBC482031 035 $a(EXLCZ)991000000000707663 100 $a20081201d2009 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aBiotech funding trends$b[electronic resource] $einsights from entrepreneurs and investors /$fAlexandra Carina Gruber 210 $aWeinheim $cWiley-Blackwell$dc2009 215 $a1 online resource (212 p.) 300 $aDescription based upon print version of record. 311 $a3-527-32435-6 320 $aIncludes bibliographical references (p. 137-139) and index. 327 $aBiotech Funding Trends: Insights from Entrepreneurs and Investors; Contents; Preface; Acknowledgments; Limit of Liability/Disclaimer of Warranty; Executive Summary; 1 Introduction; 1.1 Development of the Private Equity and Venture Capital Market; 1.1.1 Denition; 1.1.2 Historical Background; 1.1.3 The Challenges to Private Equity in Europe; 1.1.4 Private Equity and Venture Capital Performance in Europe by Country; 1.1.5 The Future of Private Equity and Venture Capital in Europe; 1.2 Development of the Biotech Industry; 1.2.1 Definition; 1.2.2 Historical Background 327 $a1.2.3 Financing Biotech Start-ups1.2.4 Exit Routes in the Biotech Industry; 1.2.5 The Challenges to European Biotech; 1.2.6 The Future of the European Biotech Industry; 2 Methodology; 2.1 Formulating the Research Goal; 2.1.1 The Entrepreneur's Dilemma; 2.1.2 The Investor's Dilemma; 2.1.3 Financing Models; 2.1.4 Interpersonal Relationships and Cooperations; 2.1.5 Practical Guidelines for Entrepreneurs and Venture Capitalists; 2.2 Conducting the Study; 2.2.1 Qualitative Interviews; 2.2.2 Selection of Interview Partners; 2.3 Evaluating the Results; 3 Data Analysis and Interpretation of Results 327 $a3.1 Description of Interview Partners3.1.1 Entrepreneurs; 3.1.2 Venture Capitalists; 3.1.3 Other Investors; 3.2 Major Characteristics of an Entrepreneur; 3.2.1 The Dual Role of the Entrepreneur; 3.3 Major Characteristics of a Venture Capitalist; 3.3.1 Global Reach of the Fund; 3.4 The Most Important Partnering Criteria; 3.4.1 The Entrepreneur's Perspective; 3.4.2 The Venture Capitalist's Perspective; 3.4.3 The Perspective of Other Investors; 3.5 Financing Models; 3.5.1 Most Important Financing Models; 3.5.2 New and Creative Financing Approaches 327 $a3.5.3 Differences Between Early- and Late-stage Financing3.5.4 Differences Between Early- and Late-stage Valuation Techniques; 3.6 Biotech Research Areas; 3.6.1 Vaccines; 3.6.2 Biotech Drug Development or Medical Technology and Devices?; 3.7 Alliances and Funding in the Early Stage; 3.7.1 Networking Between Venture Capitalists and Universities and Their Scientists; 3.7.2 The Role of Government Grants; 3.7.3 The Role of Business Angels; 3.7.4 Preferred Deal Structure; 3.7.5 Structuring the Board of Directors; 3.8 Alliances and Funding in the Late Stage 327 $a3.8.1 Networking with Corporate Venture Capitalists3.8.2 The Role of Banks as Capital Investors; 3.8.3 The Importance of Milestone Payments; 3.9 Exit Routes; 3.9.1 Exit Preferences; 3.9.2 The Role of New Markets; 3.9.3 Prominent European IPO Success Stories; 3.10 Primary Causes of Failure; 3.10.1 The Entrepreneur's Perspective; 3.10.2 The Venture Capitalist's Perspective; 3.10.3 The Perspective of Other Investors; 3.11 Best-practice Countries for Funding Biotech Start-ups; 3.11.1 The Entrepreneur's Perspective; 3.11.2 The Venture Capitalist's Perspective 327 $a3.11.3 The Perspective of Other Investors 330 $aBased on interviews with successful biotech entrepreneurs and high-level investors as well as case studies, this title provides a comprehensive overview of current trends in biotech funding. In particular, it illustrates the tensions between both sides based on their different backgrounds and expectations. The book outlines the various funding opportunities for the biotech industry and identifies ways for both sides to overcome their existing prejudices in order to successfully thrive in a competitive environment.A must-have for biotech entrepreneurs and investors, as well as invaluable su 606 $aBiotechnology industries$zEurope$xFinance 606 $aBiotechnology$zEurope 615 0$aBiotechnology industries$xFinance. 615 0$aBiotechnology 676 $a228.4/36606094 676 $a338.476606 700 $aGruber$b Alexandra Carina$f1971-$01731594 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910841167403321 996 $aBiotech funding trends$94144529 997 $aUNINA